SXTP

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

60 Degrees Pharmaceuticals Inc revenue for the last quarter amounts to 256.28K USD, increased 75.42 % YoY.

60 Degrees Pharmaceuticals Inc. EPS for the last quarter amounts to -1.55 USD, decreased -183.78 % YoY.

60 Degrees Pharmaceuticals Inc (SXTP) has 3 emplpoyees as of December 15 2025.

Today SXTP has the market capitalization of 3.28M USD.